Skip to main content
S&P 5007,582.98-1.37%DOW53,141.78-0.40%NASDAQ25,077.71-2.56%BTC$78,827.00-0.62%ETH$2,364.58+0.04%GOLD$4,126.60+1.32%OIL$89.76+1.86%
Smart Investors Daily
SID Premium
NA

NASDAQ · NAMSW

NewAmsterdam Pharma Company N.V.

Healthcare · Biotechnology

$9.50

Up+$0.00 (+0.00%)

Updated Nov 5, 2026, 2:54 PM

SID Score

3.5/10

Composite research score

Smart Money

54/100

Neutral

Market cap
2.82B
P/E ratio
-19.49
Dividend yield
0.00%
52-week range
$8.25 – $30.45
Volume
1.89K
Avg. volume
3.52K

Price performance · NAMSW

NAMSW price history

1M range · 9 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

NAMSW closed at $9.50 after 9 trading sessions, down 13.24% for the selected period.

Last close
$9.50
Period change
-13.24%
Period low
$8.25
Period high
$11.00
Daily close
View OHLC price history
NAMSW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$9.26$9.50$9.25$9.501.89K
Nov 2, 2026$9.50$9.55$9.49$9.5015.35K
Oct 30, 2026$9.23$9.23$8.68$8.98452.41K
Oct 26, 2026$8.25$8.25$8.25$8.25241
Oct 23, 2026$9.40$9.40$9.25$9.251.85K
Oct 21, 2026$11.00$11.00$10.96$11.00912
Oct 20, 2026$10.20$10.75$10.20$10.75767
Oct 16, 2026$9.10$9.10$8.82$9.001.93K
Oct 13, 2026$10.70$10.95$9.79$10.95951

Latest NAMSW news

The latest Smart Investors Daily articles mentioning NAMSW.

Stock researchCompany · Overview

NAMSW research

Overview

Company profile and research snapshot.

Company profile

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?

NewAmsterdam Pharma recently dosed the first participant in SPINOZA, a Phase 2b, randomized, double-blind, placebo-controlled trial evaluating its CETP inhibitor obicetrapib in about 400 people with preclinical Alzheimer’s disease. This trial is unusual in that it targets biomarker changes such as plasma p-tau217 in carefully selected ApoE genotype subgroups before symptoms fully develop. We’ll now examine how launching the genotype-stratified SPINOZA Alzheimer’s trial could influence...

Yahoo · Oct 2, 2026

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s

Yahoo · Sep 29, 2026

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures- NAARDEN, the Netherlands and MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a lat

Yahoo · Sep 23, 2026

NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco, combining 10 mg of obicetrapib with 10 mg of ezetimibe. These are the products’ first global approvals. The medicines lower low-density lipoprotein cholesterol, or LDL-C, commonly called […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By